The @entity299 ( @entity299 ), with over 20,500 subjects, is the largest trial of statin therapy ever conducted. It provides important and definitive new information on @entity1 , the elderly, @entity6 , and @entity1 with low baseline @entity165 pre-treatment and those with prior occlusive non-coronary vascular disease. It is a prospective double blind randomised controlled trial with a 2 x 2 factorial design investigating prolonged use (>5 years) of @entity3413 40 mg and a cocktail of antioxidant vitamins (650 mg @entity270 , 250 mg @entity620 and 20 mg @entity2066 ). The @entity299 specifically included @entity1 with high risk for @entity301 ( @entity301 ) but characteristics that excluded them from participation in previous statin trials. @entity3413 40 mg treatment showed benefit across all @entity1 groups regardless of age, gender or baseline @entity165 value and proved safe and well tolerated. Results show a 12% reduction in total mortality, a 17% reduction in vascular mortality, a 24% reduction in @entity301 events, a 27% reduction in all @entity64 and a 16% reduction in non-coronary revascularisations. Among high-risk @entity1 in this western population (with a minimum total @entity165 [TC] > or = 3.5 mmol/l at entry) there appears to be no threshold @entity165 value below which statin therapy is not associated with benefit; even among those with pre-treatment @entity165 levels below current national recommended targets. Over the 5.5 year study period @entity1 and their doctors were encouraged to add an active non-study statin to the study regimen if they wished to do so. Thus the trial eventually had only two-thirds complying with the original intention-to-treat design. Nevertheless, results were highly significant for the study statin-- @entity3413 40 mg once daily. Preliminary results of the @entity299 are negative for the antioxidant vitamin cocktail but provide reassurance that @entity2221 do no harm.

The MRC/BHF XXXX : preliminary results.

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient', 'people'] @entity64 :: ('MESH:D020521', 'Disease') :: ['strokes'] @entity3413 :: ('MESH:D019821', 'Chemical') :: ['Simvastatin', 'simvastatin'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetics'] @entity270 :: ('MESH:D014810', 'Chemical') :: ['vitamin E'] @entity620 :: ('MESH:D001205', 'Chemical') :: ['vitamin C'] @entity2066 :: ('MESH:D019207', 'Chemical') :: ['beta-carotene'] @entity301 :: ('MESH:D003327', 'Disease') :: ['CHD', 'coronary heart disease'] @entity2221 :: ('CHEBI:33229', 'Chemical') :: ['vitamins'] @entity299 :: ('MESH:D006331', 'Disease') :: ['Heart Protection Study', 'HPS'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity299 :: (MESH:D006331,Disease) :: ['Heart Protection Study']
